Research Article
Outcomes of Bariatric Surgery in Morbidly Obese Patients with Multiple Sclerosis
Table 1
Baseline characteristics of the surgical and control groups.
| | | Surgical group () | Control group () |
| | Age, y, mean (SD) | 51 (10.5) | 48.2 (12.2) | | Gender F-M | 15-1 | 13-3 | | BMI, kg/m2, mean (SD) | 45 (4.7) | 43.6 (3.7) | | Type of MS | | | | Relapsing remitting (RRMS) | 11 | 15 | | Secondary progressive (SPMS) | 2 | 1 | | Primary progressive (PPMS) | 3 | 0 | | Medications | | | | Dalfampridine use | 1 | 2 | | Corticosteroids | 0 | 0 | | Glatiramir | 5 | — | | Interferon beta-1a | 5 | — | | Natalizumab | 2 | — | | Disease duration, years, mean (SD) | 15.6 (11.5) | 9 (4.3) | | Length of follow-up, months, mean (SD) | 41.2 (28) | 39.8 (7) | | Number of acute MS exacerbations | 2 | 4 |
|
|
Indicated to help improve walking in adults with MS.
Exacerbations calculated over length of follow-up period noted in table.
|
